

Publications



Papers published from the study

1. **Dar SA**, Bhattacharya SN, Das S, Ramachandran VG, Banerjee BD, Arora P. Response of T-cell subpopulations to superantigen and recall antigen stimulation in systemic sclerosis. *Indian J Dermatol* 2012;57(3):175-80.
2. **Dar SA**, Das S, Ramachandran VG, Bhattacharya SN, Mustafa MD, Banerjee BD, Verma P. Alterations in T-lymphocyte sub-set profiles and cytokine secretion by PBMC of systemic lupus erythematosus patients upon in vitro exposure to organochlorine pesticides. *Journal of Immunotoxicology* 2012;9(1):85-95.
3. **Dar SA**, Das S, Bhattacharya SN, Ramachandran VG, Ahmed T, Banerjee BD, Sonthalia S, Sood V, Banerjee AC. Possible role of superantigens in inducing autoimmunity in Pemphigus patients. *Journal of Dermatology* 2011;38(10):980-987.

Manuscripts communicated for publication

1. **Dar SA**, Das S, Ramachandran VG, Bhattacharya SN, Banerjee BD. Cytokine gene polymorphisms and susceptibility to common autoimmune skin diseases.
2. **Dar SA**, Das S, Banerjee BD, Ramachandran VG, Bhattacharya SN. Effect of immunosuppressive treatment of pemphigus patients on T-cell subsets and cytokine levels.
3. **Dar SA**, Das S, Bhattacharya SN, Banerjee BD, Ramachandran VG. Modulation of Immune response after immunosuppressive treatment of systemic sclerosis and systemic lupus erythematosus patients.

Papers presented in conferences

1. Poster presentation at the **5th Congress of the Federation of Immunological Societies of Asia Oceania (FIMSA, 2012)**, held at the Le Meridien Hotel, New Delhi, India, March 14-17, 2012 on the topic entitled “Alterations in T-lymphocyte subset profiles and cytokine secretion by PBMC of systemic lupus erythematosus patients upon in-vitro exposure to organochlorine pesticides.”
2. Poster presentation at the **5th Congress of the Federation of Immunological Societies of Asia Oceania (FIMSA, 2012)**, held at the Le Meridien Hotel, New Delhi, India, March 14-17, 2012 on the topic entitled “Response of T-lymphocyte subpopulations to superantigen and recall antigen stimulation in systemic sclerosis.”
3. Poster presentation at the **37th Annual Conference of Indian Immunology Society** at University of Jammu (J&K), India from 7th - 9th February, 2011 on the topic entitled “Superantigen induced T-cell alterations – a possible role in modulating the pathogenic autoantibody response in pemphigus.”
4. Poster presentation at the **MICRO-D-CON, 2010** (2nd annual conference on “Future of Microbiology”), 12th – 13th March, 2010 at India Habitat Centre, New Delhi, India on the topic entitled “Possible Role of Superantigens in Inducing Autoimmunity in Pemphigus Patients” and was awarded **SANJAY SARDANA MEMORIAL AWARD** (Cash prize and Certificate for best poster presentation in ‘Free Poster Category’).

Other publications

1. Lata S, Sood V, **Dar SA**, Banerjea AC, Das S, Ramachandran VG. Characterization of natural HIV-1 Tat and Vpr variants from Northern India. *BMC Infectious Diseases* 2012; 12:8.
2. Das S, Saha R, Bhattacharya SN, Mishra K, **Dar SA**. Hyalohyphomycosis: an unusual presentation and review of literature. *Indian Journal of Medical Specialities* 2010;1(2):123-129.
3. Das S, Saha R, **Dar SA**, Ramachandran VG. Acremonium Species: A Review of the Etiological Agents of Emerging Hyalohyphomycosis. *Mycopathologia* 2010;170:361–375.
4. Talwar GP, **Dar SA**, Rai MK, Reddy KVR, et al. A novel polyherbal microbicide with inhibitory effect on bacterial, fungal and viral genital pathogens. *International Journal of Antimicrobial Agents* 2008;32:180–185.
5. Bhengraj AR, **Dar SA**, Talwar GP and Mittal A. Potential of a novel polyherbal formulation BASANT for prevention of Chlamydia trachomatis infection. *International Journal of Antimicrobial Agents* 2008;32:84–88.

Consent form

I _____

S/O; D/O; W/O _____

Resident of _____

state that I have been counseled about the study entitled “Molecular analysis of cytokine polymorphism in conjunction with the study of immune response to common recall antigens, superantigens and xenobiotic compounds in autoimmune skin diseases” and have been explained about its applications, mode of conduct, duration and implications. I unhesitatingly do hereby give my consent for enrollment voluntarily in the above study for relevant skin testing and collection of my blood sample for analysis. I have been explained that this small volume of blood is essentially harmless to me and that I shall not be issued any results or reports. All this has been explained to me in a language I understand.

Signature of Witness

Name.....

Address.....

.....

Date:

Signature/LTI of the Volunteer

.....

Signature of the Doctor

Name.....

PATIENT PROFORMA

S. No:	Hospital No.: 1.	Date:
	2.	
Name:	Age:	Sex: DOA:
Address:	Phone No:	
Duration of Diseases:		
H/o Remission/Relapses/Recurrences:	Y/N	No. in past
Seasonality:	Y/N	
Identified precipitating factor:	Y/N	If yes, specify

AT ENTRY

Weight:	Height:
---------	---------

DIAGNOSIS

Pemphigus:
Scleroderma:
SLE:
Others:

CLINICAL FEATURES

Joint Pain/Arthritis	Y/N	Grade:		
X ray findings	Chest:	Date:	Film No:	Findings:
	Limbs:	Date:	Film No:	Findings:

TREATMENT HISTORY

Antibiotics:	Y/N	Drug:	Duration:	Last dose:
Steroids:	Y/N	Drug:	Duration:	Last dose:
Sulphasalazine:	Y/N	Drug:	Duration:	Last dose:
Other immunosuppressive:	Y/N	Drug:	Duration:	Last dose:
Cyclosporine A, Methotrexate:	Y/N	Drug:	Duration:	Last dose:

INVESTIGATION**Date****INVESTIGATION****Date**

Hb
 ESR
 LFT
 S. albumin
 S. bilirubin
 SGOT

TLC
 DLC
 S. Protein
 S. globulin
 SGPT
 S. Alk PO₄ase

SKIN BX

Date: BX no: Report:

ACUTE PHASE REACTANTS**Date**

CRP:
 ASO:
 ANA:
 RA (Rose-Waaler):
 Ro/La antibodies:
 ELISA (Total Ig):

Stool Examination: Routine Microscopic
 Semi-quantative egg Burden (Kato-Katz technique)

SKIN TESTING**Diameter in mm****Data entry**

Candida (1:1000; 0.1ml):
 Tuberculin (PPD-5TU; 0.1ml):
 Tetanus toxoid (TT-5-25Lf; 0.5ml):
 Diphtheria (DPT-0.5ml):

MANAGEMENT

Date Drug Duration End of therapy